



rs841853 of SLC2A1 Gene Polymorphism and Dyslipidemia Among Javanese Type 2 Diabetes Mellitus Patients

Yanuarita Tursinawati^{1,*} Ari Yuniastuti²

¹ Universitas Muhammadiyah Semarang, Semarang, Central Java 50275, Indonesia

² Universitas Negeri Semarang, Semarang, Central Java 50229, Indonesia
yanuarita_tursina@unimus.ac.id

Abstract. Type 2 Diabetes Mellitus (T2DM) is a chronic disease indicated by blood sugar level disorder and also influenced by genetic and environmental factors. Many diabetes patients experience dyslipidemia, which is known as diabetic dyslipidemia. In the latest research, SLC2A1 gene polymorphism is strongly related to T2DM. This research aimed to investigate the involvement of rs841853 of SLC2A1 gene polymorphism in Javanese diabetes patients with dyslipidemia. This cross-sectional study involved 107 T2DM patients as the sample to verify polymorphism. The occurrence of polymorphism was done using the PCR-RFLP method. The mean of the laboratory characteristic among groups was tested using an independent t-test with a significance of $p < 0.05$. In both groups, G allele (wild type) and GG genotype were mostly found. There was no difference in allele frequency ($p=0.185$) and genotype frequency ($p=0.238$). The differences of laboratory characteristic between the GG genotype and TG + TT genotype, either in dyslipidemia or non-dyslipidemia, showed no significance ($p>0.05$). Rs841853 of SLC2A1 gene polymorphism was not a significant risk factor for dyslipidemia in Javanese T2DM patients.

Keywords: Polymorphism, SLC2A1 Gene, Dyslipidemia, Type 2 Diabetes Mellitus, Javanese.

1. Introduction

Type 2 diabetes mellitus (T2DM) is a chronic disease indicated by blood sugar level disorder and also influenced by genetic and environmental factors. Genome-wide association studies (GWAS), which is a wide-scale genome study association, succeed in identifying genetic locus related to T2DM. Some genetic variations studied in Indonesia, especially in the Javanese ethnicity, which is the largest ethnicity in Indonesia, such as the relation of CAPN10 SNP-19, MTNR1B rs10830963, and SLC2A1 rs841853 polymorphism [1]–[3]. The polymorphism of MTNR1B rs10830963 and SLC2A1 rs841853 gene related to the role of melatonin in the pathophysiology of diabetes mellitus. MTNR1B gene is related to its function as a melatonin receptor, a significant hormone for carbohydrate metabolism, while the SLC2A1 gene codes member one protein glucose transporter

(GLUT1). It facilitates the transportation of protein glucose through the plasma membrane of mammal cells. In some studies, it was proven that the SLC2A1 polymorphism is correlated to Type 2 Diabetes Mellitus (T2DM), diabetic nephropathy and retinopathy, renal cell carcinoma, and the latest study found that it is correlated with breast cancer and age-related macular degeneration [4]–[8].

Many diabetes patients experience dyslipidemia, which is known as diabetic dyslipidemia, due to a metabolism disorder of simultaneous carbohydrate and fat as the result of insulin production defects or insulin action. Dyslipidemia is caused by a low level of high-density lipoprotein cholesterol (HDL-C), the increase of total cholesterol level, along with low-density lipoprotein cholesterol (LDL-C) and triglyceride, which contribute to cardiovascular diseases. Based on the survey by Jakarta Primary Non-communicable Disease Risk Factor Surveillance 2006, the proportion of Dyslipidemia in T2DM patients reached 67.7% (the high level of total cholesterol), 36.8% (the low level of HDL), 91.7% (high level of LDL), and 54.9% (high level of triglyceride) [9]. Hypertriglyceridemia in diabetes is caused by the excess production of Very Low-Density Lipoprotein (VLDL) by the liver [10]. A study by Yanuarita et al., 2023 shows that rs10830963 of MTNR1B polymorphism doesn't affect the case of dyslipidemia diabetes in Javanese T2DM patients [3]. However, the study analyzed the involvement of other polymorphisms, such as rs841853 of SLC2A1 (XbaI G>T), which have not been reported, so the this study interested in conducting research related to the involvement of rs841853 of SLC2A1 polymorphism in Javanese diabetes patients with dyslipidemia.

2. Methods

2.1 Design and subject of the study

The research conducted was an analytical observational study utilizing a cross-sectional approach, involving 107 patients with Type 2 Diabetes Mellitus (T2DM) selected from three community health centers in Semarang as the research sample. The participants met specific inclusion criteria, including being Javanese individuals with T2DM aged between 30 and 70 years old, and having provided signed informed consent. Ethical clearance for the research was obtained from the Research Ethics Committee at the Faculty of Medicine, Universitas Muhammadiyah Semarang, under the reference number 040/EC/FK/2019.

2.2 Genotyping of SLC2A1 Gene Polymorphism

Polymorphism occurrence was identified using the PCR-RFLP method, involving the amplification of SLC2A1. The PCR Mix consisted of 21 µl, comprising 2.5 µl of PCR buffer with MgCl₂, 0.25 µl of dNTP, 1.5 µl each of forward (5'-TGC AAC CCA TGA GCT AAC AA-3') and reverse (5'-GAA CCC AGC ACT CTG TAG CC-3') primers, 0.25 µl of DNA Taq polymerase, 1 µl of DNA sample, and 14 µl of H₂O, with a total volume of 21 µl. PCR is conditioned at 95°C predenaturation for five minutes in 33 cycles, 95°C

denaturation for 30 seconds, 60°C annealing for three seconds, 72°C elongation for one minute, and 72°C final extension for three minutes. 100µl RFLP (10µl PCR product; 5µl XbaI; 10µl enzyme buffer (10×); 75µl H₂O, 10µl BSA), then digest PCR product with enzyme mix (10µl: 10µl), then incubated at 37°C for an hour, visualized in 2% agarose gel, 120 Volt for 30 minutes. The polymorphism was observed using electrophoresis, which showed T allele (mutant type) (305bp) and G allele (wild type) (232 bp and 73 bp) [2]

2.3 Chemical clinic testing

Triglyceride, cholesterol, HDL-C, and LDL-C level was tested by taking a venous blood sample after 8 hours of fasting. Dyslipidemia diagnoses were made based on the criteria of total cholesterol >200mg/dL, LDL cholesterol levels >130mg/dL, or triglyceride levels >200mg/dL [3], [11], [12].

2.4 Data analysis

Allele frequency and SLC2A1 rs841853 genotype polymorphism were analyzed using a chi-square test. Then, it was compared with the result of chemical clinic testing among groups using the independent t-test with a significance value of $p < 0.05$.

3. Results

The allele distribution of rs841853 SLC2A1 polymorphisms was presented in Table 1. The frequency analysis from 107 T2DM patients found that 46 patients were diagnosed with dyslipidemia and 61 patients were non dyslipidemia. G allele and GG genotype were mainly found in both groups. Statistically, there was no significant difference between the allele frequency ($p=0.185$) and genotype frequency ($p=0.238$) either in dyslipidemia or non-dyslipidemia groups.

Table 1. Allele distribution of rs841853 SLC2A1 polymorphisms

		Subjects (n=107)		
		Dyslipidemia N=46	Non-Dyslipidemia N=61	p*
rs841853 SLC2A1				
Allele	G	61 (66.3%)	70 (57.4)	0.185
	T	31(33.7%)	52 (42.6%)	
Genotype	GG	21 (45.7%)	25 (41%)	0.238
	TG	19 (41.3%)	20 (32.8%)	
	TT	6 (13%)	16 (26.2%)	

* Chi Square test, $p < 0.05$ as significant result

Based on Table 2, there was no difference in the average level of laboratory characteristic between the GG genotype and TG+TT genotype, either in dyslipidemia or non-dyslipidemia groups. Nevertheless, the higher average parameter was found in the TG+TT group at BMI, FPG, HbA1C, and microalbuminuria parameters of the dyslipidemia group.

Table 2. The comparison of laboratory characteristic based on the Genotype of SLC2A1 rs841853 Polymorphism

Variable	Dyslipidemia (N= 46)		P	Non Dyslipidemia (N= 61)		P*
	GG	(TG) + (TT)		GG	(TG) + (TT)	
BMI	23.4±1.98	24.40±3.6	0.651	24.9±3.52	24.4±3.55	0.62
FPG (mg/dl)	170.4±94.6	186.36±84.4	0.384	152.±70.0	142.1±59.8	0.68
SBP (mmHg)	153.3±26.8	138±14.2	0.947	133.6±11.2	140.5±20.9	0.22
DBP (mmHg)	78.6±10.7	78.52±7.6	0.965	81.0±8.2	82.5±8.93	0.58
HbA1c	7.9±1.69	8.72±2.3	0.440	7.7±2.14	7.3±1.63	0.51
Ureum	32.4±14.7	25.40±8.1	0.085	28.7±9.9	31.9±11.95	0.29
Creatinin	0.9±0.61	0.79±0.2	0.383	0.9±0.39	1.1±0.53	0.35
Microalbumin	226.6±382.1	273.28±389	0.221	133.9±187	371.9±1348	0.63

* Independent t-test, $p < 0.05$ as significant result

4. Discussion

The finding of the study shows the most alleles found in pada SLC2A1 rs841853 polymorphism were the G allele (wild type), and the most found was the GG genotype. The previous study by Yanuarita et al., 2021 showed the same finding. However, the classification based on obesity was different from this study, which classified the group based on the case of dyslipidemia. In the mentioned study, the most found allele was also the wild-type allele (G allele) [2]. The rs841853 polymorphism represents a single nucleotide variant located within the SLC2A1 gene on chromosome 1, positioned at 43,401,438. A comprehensive meta-analysis, which examined 14 articles and 19 individual studies, investigated the association between this polymorphism and Type 2 Diabetes Mellitus (T2DM). Results indicated that within the control group, the frequency of the TT genotype was 30.9%, the TG genotype was 12.9%, and the GG genotype was 38.4%. Conversely, in the case group, the distribution of genotype frequencies was as follows: 32.9% for TT, 10.2% for TG, and 47.2% for GG. These findings suggest a potential correlation between the rs841853 polymorphism and the occurrence of Type 2 Diabetes Mellitus. It can be concluded that the finding of the study was similar to the study where

the GG genotype was the most found allele, except in the case group in which the TG genotype was the most found [5]. This polymorphism also increases the risk of Type 2 DM in Asians from 1.83 to 2.24 [5].

The respondents of this research were classified into patients with dyslipidemia and non-dyslipidemia, as the case of T2DM is often accompanied by lipid metabolism disorder. The metabolism disorder in T2DM patients is in the form of the increase of triglyceride, LDL, and VLDL levels, as well as a low level of HDL [10]. The level of LDL-C typically was not different in the control group but was different at the small dense LDL, a pro-atherogenic lipoprotein particle. Although no significant difference was found between GG and TG+TT genotypes in the dyslipidemia group, this research found higher FPG and HbA1c levels in the TG+TT dyslipidemia group. It shows that the dyslipidemia group has poor glycemic control on genotype with mutant allele (T). It is in line with research that shows that in patients with type 1 and type 2 DM, poor glycemic control could increase triglyceride serum, LDL, and VLDL levels, as well as reduce the level of HDL-C. [13] A reasonable glycemic control could lower triglyceride levels and increase HDL serum, in contrast to patients with poor glycemic control. Therefore, diabetes therapy also aims to optimize the glycemic control in diabetes patients.

In the dyslipidemia group, a higher microalbuminuria level was found in TG+TT. The level of lipoprotein a / Lp (a) is not significant in DM patients. However, research mentions that the increase of Lp (a) level is correlated to the case of microalbuminuria and renal disorder. [14], [15] It shows the possibility that the higher level of microalbuminuria in the TG +TT genotype could be attributed to the change in lipoprotein (a) level. Therefore, one of the weaknesses of this research is the absence of lipoprotein measurement to correlate with the increase of microalbuminuria. Besides, this study did not consider the use of lipid-lowering medicine such as statin. DM patients often use statin, although the use badly impacts the Glucose Homeostasis. In non-DM patients, the higher dosage of statin could increase the risk by 10%, compared to the moderate use of statin [16].

5. Conclusion

In both groups, the most found allele was the G allele (wild type), and the most found genotype was the GG genotype. There was no difference in the average level of laboratory characteristic between the GG genotype and TG+TT genotype either in dyslipidemia and or-dyslipidemia groups. Nevertheless, the higher average parameter was found in the TG+TT group at BMI, FPG, HbA1C, and microalbuminuria parameters of the dyslipidemia group. rs841853 of SLC2A1 gene polymorphism was not a significant risk factor for dyslipidemia in Javanese T2DM patients.

Authors' Contributions

YT, as the primary author, devised the analytical methods employed in the study, conducted data analysis, interpreted the findings, drafted the article, and finalized it for publication. AY contributed to data interpretation, assisted in scrutinizing the data analysis, and participated in reviewing the article. Both authors share responsibility for the manuscript's content and its submission process.

Acknowledgements

We express our gratitude to the Central Laboratory of Diponegoro University Semarang (Cebior), Semarang, and the Laboratory of the Mathematics and Natural Sciences Faculty for their invaluable assistance in sample preparation and analysis for genotyping. Their support has been instrumental in the successful execution of our research endeavors.

References

1. Y. Tursinawati, R. F. Hakim, A. Rohmani, A. Kartikadewi, and F. Sandra, "CAPN10 SNP-19 is associated with susceptibility of type 2 diabetes mellitus: A Javanese case-control study," *Indones Biomed J*, vol. 12, no. 2, pp. 109–14, 2020, doi: 10.18585/inabj.v12i2.984.
2. Y. Tursinawati, A. Kartikadewi, A. Yuniastuti, and R. Susanti, "Association of rs10830963 MTNR1B and rs841853 SLC2A1 Polymorphism with Obesity on Type 2 Diabetes Patients: An Overview of Melatonin Receptor and Transporter," *Indones Biomed J*, vol. 13, no. 2, pp. 155–62, 2021, doi: 10.18585/inabj.v13i2.1488.
3. Y. Tursinawati and A. Yuniastuti, "Rs10830963 Polymorphism of the MTNR1B Gene in Type 2 Diabetes Mellitus Patients with Dyslipidemia and Non-Dyslipidemia," in *Proceedings of the 1st Lawang Sewu International Symposium 2022 on Health Sciences (LSISHS 2022)*, 2023, vol. 1, pp. 138–145, doi: 10.2991/978-94-6463-132-6_17.
4. W. Cui *et al.*, "Relationship between five GLUT1 gene single nucleotide polymorphisms and diabetic nephropathy: A systematic review and meta-analysis," *Mol. Biol. Rep.*, vol. 39, no. 8, pp. 8551–8, 2012, doi: 10.1007/s11033-012-1711-z.
5. B. Du, S. Liu, C. Cui, S. Wang, and W. Cui, "Association between glucose transporter 1 rs841853 polymorphism and type 2 diabetes mellitus risk may be population specific," *J. Diabetes*, vol. 5, no. 3, pp. 291–9, 2013, doi: 10.1111/1753-0407.12042.
6. D. C. Baas *et al.*, "Multicenter cohort association study of SLC2A1 single nucleotide polymorphisms and age-related macular degeneration," *Mol. Vis.*, vol. 18, no. October 2011, pp. 657–74, 2012.
7. C. C. Hsu *et al.*, "Genetic variation of Glucose Transporter-1 (GLUT1) and

- albuminuria in 10,278 European Americans and African Americans: A case-control study in the Atherosclerosis Risk in Communities (ARIC) Study,” *BMC Med. Genet.*, vol. 12, pp. 1–13, 2011, doi: 10.1186/1471-2350-12-16.
8. C. Granier, K. Makni, L. Molina, B. Jardin-Watelet, H. Ayadi, and F. Jarraya, “Gene and protein markers of diabetic nephropathy,” *Nephrol. Dial. Transpl.*, vol. 23, no. 3, pp. 792–9, 2008, doi: 10.1093/ndt/gfm834.
 9. Perkeni, “Pedoman Pengelolaan Dislipidemi di Indonesia 2019,” *PB. Perkeni*, p. 9, 2019.
 10. M. Kenneth R. Feingold, *Dyslipidemia in Diabetes*. 2020.
 11. L. W. Unger *et al.*, “Patterns and prevalence of dyslipidemia in patients with different etiologies of chronic liver disease,” *Wien Klin Wochenschr*, vol. 131, no. 17–18, pp. 395–403, 2019, doi: 10.1007/s00508-019-01544-5.
 12. P. S. Jellinger *et al.*, “American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Dyslipidemia and Prevention of Cardiovascular Disease,” *Endoc Pr.*, vol. 23, no. April, pp. 1–87, 2017, doi: 10.4158/EP171764.APPGL.
 13. I. J. Goldberg, “Diabetic dyslipidemia - Causes and consequences,” *J. Clin. Endocrinol. Metab.*, vol. 86, no. 3, pp. 965–71, 2001, doi: 10.1210/jc.86.3.965.
 14. P. N. Durrington, J. D. Schofield, T. Siahmansur, and H. Soran, “Lipoprotein (a): Gene genie,” *Curr. Opin. Lipidol*, vol. 25, no. 4, pp. 289–96, 2014, doi: 10.1097/MOL.0000000000000096.
 15. B. Enkhmaa, E. Anuurad, and L. Berglund, “Lipoprotein (a): Impact by ethnicity and environmental and medical conditions,” *JLR*, vol. 57, no. 7, pp. 1111–25, 2016, doi: 10.1194/jlr.R051904.
 16. D. Preiss and N. Sattar, “Statins and the risk of new-onset diabetes: A review of recent evidence,” *Curr. Opin. Lipidol*, vol. 22, no. 6, pp. 460–6, 2011, doi: 10.1097/MOL.0b013e32834b4994.

Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The images or other third party material in this chapter are included in the chapter's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the chapter's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

